Few Adolescents Receive Gender Affirming Care
As debates around healthcare for transgender youth intensify in the United States, recent research provides crucial insights into the scale of gender-affirming medical care. A study published in a leading medical journal reveals that fewer than 1 in 1,000 U.S. adolescents with commercial insurance received puberty blockers or hormone therapies between 2018 and 2022. These findings debunk common misconceptions about the prevalence of such treatments.
Analyzing a database covering over 5 million adolescents aged 8 to 17, researchers identified only 926 individuals who received puberty blockers and 1,927 who were prescribed hormones during the five-year period. Notably, no children under the age of 12 were prescribed hormones, demonstrating that healthcare providers adhere to strict guidelines when initiating treatment. The study underscores the cautious approach taken by medical professionals in addressing gender dysphoria among minors.
The findings come as at least 26 states have passed laws restricting or banning gender-affirming medical care for minors, with many of these laws facing legal challenges. A pivotal decision from the U.S. Supreme Court on a case originating in Tennessee is expected later this year.
Lead author Landon Hughes, a Harvard public health researcher, stated that the study aimed to dispel myths about the widespread use of gender-affirming medications. “We are not seeing inappropriate use of this sort of care. It’s certainly not happening at the rate at which people often think it is,” Hughes noted.
The research excluded adolescents covered by Medicaid, the federal-state program for low-income individuals, potentially leaving out a significant portion of the population. It also did not explore gender-affirming surgeries, which other studies have shown to be exceedingly rare among minors.
Experts in adolescent healthcare emphasize that not all transgender youth pursue medical treatments, as gender identity develops differently for each individual. Dr. Scott Leibowitz, a co-lead author of the adolescent standards of care for the World Professional Association for Transgender Health, highlighted the importance of personalized care that involves specialists and family support.
The study’s findings are expected to inform public discourse and policymaking around transgender healthcare, emphasizing the need for evidence-based approaches. For more on gender-affirming healthcare and its role in adolescent development, consult credible resources on public health and medical ethics.
